Prostate Cancer News

Here are some updates in the world of radiogland therapy, prostate cancer treatments, research, and more.

Pluvicto Moves into Earlier Treatment Stages - June 2025

A Phase III trial called PSMAddition evaluated Pluvicto (lutetium‑177‑PSMA‑617) combined with hormone therapy in men with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). Initial findings show a statistically significant improvement in radiographic progression-free survival (rPFS) and a trend toward better overall survival compared to hormone therapy alone

Source: Novartis News

New Combination Data for Xofigo - June 2025

At ASCO 2025, updated trial results revealed that pairing Xofigo (radium‑223) with enzalutamide significantly improved PSA responses and rPFS in men with bone-metastatic metastatic castration-resistant prostate cancer (mCRPC), compared to enzalutamide alone

Source: Oncology News Central

Pluvicto Gains FDA Label Expansion for Earlier Use - March 2025

The FDA granted an expanded indication for Pluvicto (lutetium‑177‑PSMA‑617), allowing its use in men with PSMA-positive metastatic castration-resistant prostate cancer who are hormone therapy-resistant but chemotherapy-naïve. The decision is based on the pivotal PSMAfore Phase III trial, which demonstrated that Pluvicto more than doubled radiographic progression-free survival (rPFS)—11.6 months vs. 5.6 months—compared to a change in androgen receptor pathway inhibitors

Source: Cancer Network